Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLINICAL OUTCOME OF GLIOSARCOMA COMPARED WITH GLIOBLASTOMA-MULTIFORME- NORTH CENTRAL CANCER-TREATMENT GROUP RESULTS
Autore:
GALANIS E; BUCKNER JC; DINAPOLI RP; SCHEITHAUER BW; JENKINS RB; WANG CH; OFALLON JR; FARR G;
Indirizzi:
MAYO CLIN & MAYO FDN,DEPT ONCOL,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT ONCOL ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT NEUROL ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL ROCHESTER MN 55905 MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES ROCHESTER MN 55905 N CENT CANC TREATMENT GRP ROCHESTER MN 00000
Titolo Testata:
Journal of neurosurgery
fascicolo: 3, volume: 89, anno: 1998,
pagine: 425 - 430
SICI:
0022-3085(1998)89:3<425:COOGCW>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADIATION-THERAPY; SARCOMATOUS COMPONENT; MIXED GLIOBLASTOMA; GLIOMA; TUMOR;
Keywords:
GLIOSARCOMA; GLIOBLASTOMA MULTIFORME; BRAIN NEOPLASM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
E. Galanis et al., "CLINICAL OUTCOME OF GLIOSARCOMA COMPARED WITH GLIOBLASTOMA-MULTIFORME- NORTH CENTRAL CANCER-TREATMENT GROUP RESULTS", Journal of neurosurgery, 89(3), 1998, pp. 425-430

Abstract

Object. Gliosarcoma, a rare malignancy of the central nervous system,consists of gliomatous and sarcomatous elements. There are conflicting reports regarding its aggressiveness and cell line of origin compared with those of glioblastoma multiforme (GBM). The goal of this study was to compare clinicopathological features such as disease-free survival time and actual survival time in patients with gliosarcoma with a matched group of patients with GEM as well as with the entire group ofpatients with GEM. Methods. The authors report on 18 cases of gliosarcoma derived from a series of 748 Grade 4 astrocytoma cases that were part of four consecutive randomized Phase III trials conducted between1979 and 1996. In this series the gliosarcoma group represented only 2.4% of all GBMs and included 11 men and seven women with a median ageof 61.5 years (range 31-81 years). The median tumor size was 5 cm (range 2-8 cm). The locations, all supratentorial, included temporal in 44%, parietal in 28%, frontal in 17%, and occipital in 11%. The 18 patients with gliosarcomas, all Grade 4 (World Health Organization classification), were compared with the entire group of 730 patients with GEMand a control group of 18 patients with GBM matched for known prognostic factors including patient age, randomization date, performance status, extent of resection, and protocol number. Patients in all treatment groups received radiation and nitrosourea-based chemotherapy. The median time to progression and the median survival times for the patients with gliosarcoma were 28.0 and 35.1 weeks as compared with 24.7 and41.6 weeks for the entire group of patients with GEM (log rank test, p = 0.94 and 0.27, respectively) and 16.7 and 34.4 weeks in the control group (p = 0.20 and 0.84, respectively). In previous molecular cytogenetic analyses of gliosarcoma these authors have shown similar genetic changes in the gliomatous and sarcomatous components. Conclusions. The data obtained in this study support the conclusion that gliosarcomashares significant clinical and genetic similarities with GEM and that the same principles should be applied for patient enrollment in research protocols and treatment for these two kinds of tumor.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 08:02:06